ES2570784T3 - Piridinas sustituidas como bloqueadores de los canales de sodio - Google Patents
Piridinas sustituidas como bloqueadores de los canales de sodioInfo
- Publication number
- ES2570784T3 ES2570784T3 ES11813366T ES11813366T ES2570784T3 ES 2570784 T3 ES2570784 T3 ES 2570784T3 ES 11813366 T ES11813366 T ES 11813366T ES 11813366 T ES11813366 T ES 11813366T ES 2570784 T3 ES2570784 T3 ES 2570784T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- alkyl
- group
- formula
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto que tiene la Fórmula I:**Fórmula** en la que: A1-X-A2- es:**Fórmula** en la que: R12a, R12b, R12c, R12d, y R12e, que pueden ser idénticos o diferentes, se seleccionan del grupo que consiste en: a) hidrógeno; b) halo; c) nitro; d) ciano; e) hidroxi; f) amino; g) alquilamino; h) dialquilamino; i) haloalquilo; j) hidroxialquilo; k) alcoxi; l) haloalcoxi; m) ariloxi; n) aralquiloxi; o) alquiltio; p) carboxamido; q) sulfonamido; r) alquilcarbonilo; s) arilcarbonilo; t) alquilsulfonilo; u) arilsulfonilo; v) ureido; w) guanidino; x) carboxi; y) carboxialquilo; z) alquilo; aa) cicloalquilo sustituido opcionalmente; bb) alquenilo sustituido opcionalmente; cc) alquinilo sustituido opcionalmente; dd) arilo sustituido opcionalmente; ee) heteroarilo sustituido opcionalmente; y ff) heterociclo sustituido opcionalmente; o R12a y R12b, o R12b y R12c, o R12c y R12d, o R12d y R12e, tomados conjuntamente con los átomos de carbono a los que están unidos forman un grupo cicloalquilo o heterociclo sustituido opcionalmente de 5 ó 6 miembros, R1a se selecciona del grupo que consiste en: a) alquilo sustituido opcionalmente; b) (heterociclo)alquilo ; c) (heteroaril)alquilo; d) (amino)alquilo; e) (alquilamino)alquilo; f) (dialquilamino)alquilo; g) (carboxamido)alquilo; h) (ciano)alquilo; i) alcoxialquilo; j) hidroxialquilo; k) heteroalquilo; l) heterociclo sustituido opcionalmente; m) -SO2R6; y n) -COR7; en el que: R6 se selecciona del grupo que consiste en: a) alquilo sustituido opcionalmente; b) cicloalquilo sustituido opcionalmente; c) arilo sustituido opcionalmente; d) heteroarilo sustituido opcionalmente; e) amino; f) alquilamino; g) dialquilamino; h) cicloalquilamino; i) heterocicloalquilamino; j) heteroarilamino; k) arilamino; y l) alquenilo sustituido opcionalmente; R7 se selecciona del grupo que consiste en: a) heteroarilo sustituido opcionalmente;**Fórmula**
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426318P | 2010-12-22 | 2010-12-22 | |
PCT/IB2011/003137 WO2012085650A1 (en) | 2010-12-22 | 2011-12-21 | Substituted pyridines as sodium channel blockers |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2570784T3 true ES2570784T3 (es) | 2016-05-20 |
Family
ID=45531451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11813366T Active ES2570784T3 (es) | 2010-12-22 | 2011-12-21 | Piridinas sustituidas como bloqueadores de los canales de sodio |
Country Status (10)
Country | Link |
---|---|
US (1) | US9656959B2 (es) |
EP (1) | EP2655330B1 (es) |
JP (1) | JP2014500303A (es) |
KR (1) | KR20130119964A (es) |
CN (1) | CN103429571A (es) |
AU (1) | AU2011346751A1 (es) |
CA (1) | CA2822789A1 (es) |
ES (1) | ES2570784T3 (es) |
WO (1) | WO2012085650A1 (es) |
ZA (1) | ZA201303780B (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011158108A2 (en) | 2010-06-16 | 2011-12-22 | Purdue Pharma L.P. | Aryl substituted indoles and the use thereof |
US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
CA2811479A1 (en) | 2010-09-17 | 2012-03-22 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
US9045435B2 (en) | 2010-10-05 | 2015-06-02 | Purdue Pharma, L.P. | Quinazoline compounds as sodium channel blockers |
JP5941546B2 (ja) | 2011-09-02 | 2016-06-29 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリミジン |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
EP2870138B1 (en) | 2012-07-06 | 2018-08-22 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
ES2680246T3 (es) | 2013-03-04 | 2018-09-05 | Purdue Pharma Lp | Pirimidincarboxamidas como bloqueantes de canal de sodio |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
CA2898679A1 (en) | 2013-03-14 | 2014-09-25 | Xenon Pharmaceuticals Inc. | Substituted triazolopyridines and methods of use thereof |
EP2968307A4 (en) * | 2013-03-15 | 2017-01-04 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
EP2970156B1 (en) | 2013-03-15 | 2018-07-25 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
CN105793238B (zh) | 2013-11-27 | 2019-12-24 | 基因泰克公司 | 经取代的苯甲酰胺及其使用方法 |
DK3080134T3 (en) * | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
US9745287B2 (en) | 2013-12-20 | 2017-08-29 | Purdue Pharma L.P. | Pyrimidines and use thereof |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
JP6337124B2 (ja) * | 2013-12-23 | 2018-06-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | インダゾール及びその使用 |
EP3089978B1 (en) | 2013-12-30 | 2018-08-29 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
EP3097078B1 (en) | 2014-01-24 | 2022-05-25 | Purdue Pharma LP | Pyridines and pyrimidines and use thereof |
US10738026B2 (en) | 2014-02-12 | 2020-08-11 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
CA2948144A1 (en) | 2014-05-06 | 2015-11-12 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
EP3154972A4 (en) | 2014-06-13 | 2017-11-22 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
MA40170A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés hétérocycliques de morphinan et leur utilisation |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CN107613965A (zh) | 2015-02-19 | 2018-01-19 | 普渡制药公司 | 用于减少胃排空的方法和组合物 |
MX2017014715A (es) | 2015-05-22 | 2018-03-16 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas. |
ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
EP3356360A1 (en) | 2015-09-28 | 2018-08-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
KR102475128B1 (ko) | 2015-11-30 | 2022-12-07 | (주)아모레퍼시픽 | Entpd4 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법 |
KR102541256B1 (ko) | 2015-11-30 | 2023-06-12 | (주)아모레퍼시픽 | Lipa 억제를 통한 흑색종 예방 또는 치료제, 및 그 스크리닝 방법 |
US20170189097A1 (en) * | 2016-01-05 | 2017-07-06 | Iowa Approach Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
RU2019114964A (ru) | 2016-10-17 | 2020-11-17 | Дженентек, Инк. | Терапевтические средства и способы их применения |
WO2018132533A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック, インコーポレイテッド | ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体 |
KR20200006128A (ko) | 2017-05-16 | 2020-01-17 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
CA3071861A1 (en) | 2017-08-07 | 2019-02-14 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
BR112022004495A8 (pt) * | 2019-09-12 | 2023-04-18 | Jiangxi Jemincare Group Co Ltd | Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos |
JP7479486B2 (ja) * | 2020-01-29 | 2024-05-08 | フォグホーン セラピューティクス インコーポレイテッド | 化合物およびその使用 |
CN111518025B (zh) * | 2020-05-07 | 2023-05-23 | 湖南科技学院 | 联吡啶双酰胺基作为有机人工离子通道单体的应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400845B (de) * | 1993-12-06 | 1996-03-25 | Chem Pharm Forsch Gmbh | Neue thienothiazinderivate, ein verfahren zu ihrer herstellung und ihre verwendung |
DE69635048T2 (de) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
ATE289295T1 (de) | 1997-04-22 | 2005-03-15 | Euro Celtique Sa | Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker |
US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
CA2310664C (en) | 1997-11-21 | 2008-03-11 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
MXPA00007585A (es) | 1998-02-04 | 2002-10-17 | Euro Celtique Sa | Semicarbazidas substituidas y el uso de las mismas. |
US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
WO2000057877A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
DK1169060T3 (da) | 1999-04-09 | 2006-01-16 | Euro Celtique Sa | Natriumkanalblokkerpræparater og anvendelse deraf |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
CN1321112C (zh) | 2000-03-24 | 2007-06-13 | 欧洲凯尔特股份有限公司 | 作为钠通道阻滞剂的芳基取代的吡唑、三唑和四唑化合物 |
MXPA02009619A (es) | 2000-03-31 | 2004-07-30 | Eruro Celtique S A | Aminopiridinas y su uso como anticonvulsivos y bloqueadores del canal de sodio. |
GB0014022D0 (en) | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
WO2002100433A1 (en) * | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
IL159765A0 (en) | 2001-07-16 | 2004-06-20 | Euro Celtique Sa | Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same |
AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
CA2475434C (en) | 2002-02-07 | 2011-04-05 | Hitoshi Endou | Aromatic amino acid derivatives and medicinal compositions |
PT1483247E (pt) | 2002-03-13 | 2009-08-18 | Euro Celtique Sa | Pirimidinas substituídas por arilo e a sua utilização |
US20040097569A1 (en) | 2002-07-31 | 2004-05-20 | Euro-Celtique S.A. | Aryl substituted hydantoin compounds and their use as sodium channel blockers |
AU2003257033A1 (en) | 2002-07-31 | 2004-02-16 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
US20040152696A1 (en) | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
ATE552251T1 (de) * | 2004-01-09 | 2012-04-15 | Lilly Co Eli | Thiophen- und furanverbindungen |
US20080187575A1 (en) | 2004-08-27 | 2008-08-07 | Bert Klebl | Pyrimidine Derivatives |
EP1877381A1 (en) | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
AU2006306542B2 (en) | 2005-10-21 | 2012-04-19 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
AR057218A1 (es) * | 2005-12-15 | 2007-11-21 | Astra Ab | Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato |
WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
US8389734B2 (en) | 2007-10-11 | 2013-03-05 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2010030967A1 (en) | 2008-09-12 | 2010-03-18 | Wyeth Llc | 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2010138600A2 (en) * | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
SG176828A1 (en) * | 2009-06-26 | 2012-01-30 | Pfizer | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
WO2011158108A2 (en) | 2010-06-16 | 2011-12-22 | Purdue Pharma L.P. | Aryl substituted indoles and the use thereof |
US9120752B2 (en) * | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
CA2811479A1 (en) * | 2010-09-17 | 2012-03-22 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
US9045435B2 (en) | 2010-10-05 | 2015-06-02 | Purdue Pharma, L.P. | Quinazoline compounds as sodium channel blockers |
JP5941546B2 (ja) | 2011-09-02 | 2016-06-29 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリミジン |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
WO2014016673A1 (en) | 2012-07-27 | 2014-01-30 | Purdue Pharma L.P. | Sodium channel blocking peptides and the use thereof |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
ES2680246T3 (es) | 2013-03-04 | 2018-09-05 | Purdue Pharma Lp | Pirimidincarboxamidas como bloqueantes de canal de sodio |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
EP2968307A4 (en) | 2013-03-15 | 2017-01-04 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
US9745287B2 (en) | 2013-12-20 | 2017-08-29 | Purdue Pharma L.P. | Pyrimidines and use thereof |
JP6337124B2 (ja) | 2013-12-23 | 2018-06-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | インダゾール及びその使用 |
EP3097078B1 (en) | 2014-01-24 | 2022-05-25 | Purdue Pharma LP | Pyridines and pyrimidines and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
CN107613965A (zh) | 2015-02-19 | 2018-01-19 | 普渡制药公司 | 用于减少胃排空的方法和组合物 |
-
2011
- 2011-12-21 AU AU2011346751A patent/AU2011346751A1/en not_active Abandoned
- 2011-12-21 EP EP11813366.9A patent/EP2655330B1/en active Active
- 2011-12-21 CA CA2822789A patent/CA2822789A1/en not_active Abandoned
- 2011-12-21 WO PCT/IB2011/003137 patent/WO2012085650A1/en active Application Filing
- 2011-12-21 ES ES11813366T patent/ES2570784T3/es active Active
- 2011-12-21 JP JP2013545523A patent/JP2014500303A/ja not_active Withdrawn
- 2011-12-21 US US13/996,082 patent/US9656959B2/en active Active
- 2011-12-21 KR KR1020137019142A patent/KR20130119964A/ko not_active Application Discontinuation
- 2011-12-21 CN CN201180061541XA patent/CN103429571A/zh active Pending
-
2013
- 2013-05-24 ZA ZA2013/03780A patent/ZA201303780B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2655330A1 (en) | 2013-10-30 |
US9656959B2 (en) | 2017-05-23 |
US20140005212A1 (en) | 2014-01-02 |
CA2822789A1 (en) | 2012-06-28 |
ZA201303780B (en) | 2014-03-26 |
JP2014500303A (ja) | 2014-01-09 |
WO2012085650A1 (en) | 2012-06-28 |
CN103429571A (zh) | 2013-12-04 |
KR20130119964A (ko) | 2013-11-01 |
AU2011346751A1 (en) | 2013-05-02 |
EP2655330B1 (en) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2570784T3 (es) | Piridinas sustituidas como bloqueadores de los canales de sodio | |
PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
PE20130155A1 (es) | Derivados de ariletinilo | |
TNSN08372A1 (en) | Heterocyclic amides for use as pharmaceuticals | |
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
MX371337B (es) | Compuestos para protección de células. | |
AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
RS54175B1 (en) | BROMODOMEN INHIBITORS AND THEIR APPLICATION | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
MX2009010024A (es) | Nuevo compuesto de adenina. | |
RS54638B1 (en) | HCV SERIN PROTEASE INHIBITORS DERIVED FROM MACROCYCLIC PROLINE | |
CO6210735A2 (es) | Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
PE20080855A1 (es) | Derivados de pirazina-2-carboxamida | |
NZ581438A (en) | Kallikrein 7 modulators | |
TR201907373T4 (tr) | Tetrazolinon bileşiği ve bunun kullanımı. | |
AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
AR086837A1 (es) | Moduladores heterociclicos de sintesis lipidica | |
PH12015502671A1 (en) | Heterocyclic amide compound | |
AR061806A1 (es) | Derivados de alquilpiridazina como inhibidores de 11b-hsd1 (t2d) | |
SV2011003825A (es) | Nuevos derivados de acilaminobenzamida | |
MX369801B (es) | Compuesto heterociclico sustituido con halogeno. |